Fujian Cosunter Pharmaceutical Co. Ltd   Report issue

For profit Phase 1 Phase 4
Founded: Fuzhou China (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2011
NCT01436539
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fujian Cosunter Pharmaceutical Co. Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 10